Irinotecan in the management of patients with pancreatic cancer

Mark R. Green; Melinda Harper; Ahmad Safa; Carol A. Sherman; Chaudry M. Mushtaq; Hamid Bahadori; Frank J. Brescia; Caio M.S.P. Rocha Lima

Irinotecan in the management of patients with pancreatic cancer

Mark R. Green, Melinda Harper, Ahmad Safa, Carol A. Sherman, Chaudry M. Mushtaq, Hamid Bahadori, Frank J. Brescia, Caio M.S.P. Rocha Lima

Medicine

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan (Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with previously untreated pancreatic cancer were given irinotecan and gemcitabine were promising, with two of three patients achieving a partial response. Because of the favorable outcome of the phase I study, a multicenter phase II trial was undertaken in previously untreated patients with pancreatic carcinoma. Data from other sites entering patients in this phase II study have been analyzed, and a multicenter phase III trial of single-agent gemcitabine vs the irinotecan combination in first-line treatment of patients with locally advanced or metastatic pancreatic cancer is underway.

Original language	English (US)
Pages (from-to)	31-33
Number of pages	3
Journal	ONCOLOGY
Volume	14
Issue number	12 SUPPL. 14
State	Published - Dec 1 2000

ASJC Scopus subject areas

Oncology
Cancer Research

Fingerprint Dive into the research topics of 'Irinotecan in the management of patients with pancreatic cancer'. Together they form a unique fingerprint.

Cite this

@article{e5a01533167c4b5288db4ddaea2bc5ba,

title = "Irinotecan in the management of patients with pancreatic cancer",

abstract = "Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan (Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with previously untreated pancreatic cancer were given irinotecan and gemcitabine were promising, with two of three patients achieving a partial response. Because of the favorable outcome of the phase I study, a multicenter phase II trial was undertaken in previously untreated patients with pancreatic carcinoma. Data from other sites entering patients in this phase II study have been analyzed, and a multicenter phase III trial of single-agent gemcitabine vs the irinotecan combination in first-line treatment of patients with locally advanced or metastatic pancreatic cancer is underway.",

author = "Green, {Mark R.} and Melinda Harper and Ahmad Safa and Sherman, {Carol A.} and Mushtaq, {Chaudry M.} and Hamid Bahadori and Brescia, {Frank J.} and {Rocha Lima}, {Caio M.S.P.}",

year = "2000",

month = dec,

day = "1",

language = "English (US)",

volume = "14",

pages = "31--33",

journal = "ONCOLOGY (United States)",

issn = "0890-9091",

publisher = "UBM Medica Healthcare Publications",

number = "12 SUPPL. 14",

}

TY - JOUR

T1 - Irinotecan in the management of patients with pancreatic cancer

AU - Green, Mark R.

AU - Harper, Melinda

AU - Safa, Ahmad

AU - Sherman, Carol A.

AU - Mushtaq, Chaudry M.

AU - Bahadori, Hamid

AU - Brescia, Frank J.

AU - Rocha Lima, Caio M.S.P.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan (Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with previously untreated pancreatic cancer were given irinotecan and gemcitabine were promising, with two of three patients achieving a partial response. Because of the favorable outcome of the phase I study, a multicenter phase II trial was undertaken in previously untreated patients with pancreatic carcinoma. Data from other sites entering patients in this phase II study have been analyzed, and a multicenter phase III trial of single-agent gemcitabine vs the irinotecan combination in first-line treatment of patients with locally advanced or metastatic pancreatic cancer is underway.

AB - Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan (Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with previously untreated pancreatic cancer were given irinotecan and gemcitabine were promising, with two of three patients achieving a partial response. Because of the favorable outcome of the phase I study, a multicenter phase II trial was undertaken in previously untreated patients with pancreatic carcinoma. Data from other sites entering patients in this phase II study have been analyzed, and a multicenter phase III trial of single-agent gemcitabine vs the irinotecan combination in first-line treatment of patients with locally advanced or metastatic pancreatic cancer is underway.

UR - http://www.scopus.com/inward/record.url?scp=0034564489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034564489&partnerID=8YFLogxK

M3 - Article

C2 - 11200146

AN - SCOPUS:0034564489

VL - 14

SP - 31

EP - 33

JO - ONCOLOGY (United States)

JF - ONCOLOGY (United States)

SN - 0890-9091

IS - 12 SUPPL. 14

ER -